Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Paul M. Ridker, Tom Thurén, Jean MacFadyen et al. · New England Journal of Medicine · 2017 · 9.1K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

Paul M. Ridker, Francisco Antônio Helfenstein Fonseca, Jacques Genest et al. · New England Journal of Medicine · 2008 · 6.6K citations · Full text

Medicine, Cardiology, Pharmacotherapy +10

2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk

David C. Goff, Donald M. Lloyd‐Jones, Glen C. Bennett et al. · Journal of the American College of Cardiology · 2013 · 5K citations · Full text

Medicine, Cardiology, Risk Management +14

Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes

Christopher P. Cannon, Eugene Braunwald, Carolyn H. McCabe et al. · New England Journal of Medicine · 2004 · 4.9K citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

Christopher P. Cannon, Michael A. Blazing, Robert P. Giugliano et al. · New England Journal of Medicine · 2015 · 4.4K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16